RankAlpha logo
Back to Rankings

AVTR

AvantorC
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The best bull read is that Q1 reset expectations low enough for a modest beat/reaffirm quarter to matter: management cited improved Bioscience execution, VWR stabilization, and early benefit from the Revival program, while the packet's median analyst target of $10.6333 sits above the $7.99 anchor price.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.5.
What can break
Free cash flow fell to $25.2 million from $82.1 million in the prior-year quarter, and cash and cash equivalents declined to $279.3 million from $365.4 million at December 31, 2025. [#10-Q-2026-04-29]
Momentum
62
Value
65
Sentiment
25
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.80 · Bull $10.20 · Bear $6.60
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-05 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $10.44
Why
Momentum62 · Δ7d +28.8
Value65 · Δ7d -0.5
Sentiment25 · Δ7d -7.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
62
26% active weight
Current posture
7d trendImproving
Δ7d
+28.8
Δ21d
+4.0
Value
65
39% active weight
Current posture
7d trendFlat
Δ7d
-0.5
Δ21d
-0.2
Sentiment
25
34% active weight
Current posture
7d trendSoftening
Δ7d
-7.3
Δ21d
-7.1
Why this grade

Composite grade C. Momentum 62.4 / Value 64.8 / Sentiment 24.8

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$7.56B
Beta
0.94
Shares Out
682.76M
P/E (TTM)
12.5
P/S (TTM)
1.23
P/FCF (TTM)
15.48
Rev YoY
0.0%
EPS YoY
-32.3%
Gross Margin
+31.0%
Op Margin
+4.0%
Net Debt
$3.77B
Current Ratio
1.76
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology